Published in
Elsevier, The Lancet Infectious Diseases, 10(21), p. 1383-1394, 2021
DOI: 10.1016/s1473-3099(21)00200-0
Links
Tools
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial
Journal article published in 2021 by
Keith J. Chappell,
Francesca L. Mordant 
,
Zheyi Li,
Danushka K. Wijesundara,
Paula Ellenberg,
Julia A. Lackenby,
Stacey T. M. Cheung,
Naphak Modhiran,
Michael S. Avumegah,
Christina L. Henderson,
Kym Hoger,
Paul Griffin,
Jillian Bennet,
Luca Hensen,
Wuji Zhang
and other authors.
,
Zheyi Li,
Danushka K. Wijesundara,
Paula Ellenberg,
Julia A. Lackenby,
Stacey T. M. Cheung,
Naphak Modhiran,
Michael S. Avumegah,
Christina L. Henderson,
Kym Hoger,
Paul Griffin,
Jillian Bennet,
Luca Hensen,
Wuji Zhang
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 